---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-24-119041"
form_type: "8-K"
ticker: "BCLI"
cik: "0001137883"
company_name: "BRAINSTORM CELL THERAPEUTICS INC."
filed_at: "2024-11-14T23:59:59+00:00"
generated_at: "2026-05-30T00:16:24.232384+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# BrainStorm Q3 net loss widens to $2.7M, cash at $0.35M; advancing NurOwn Phase 3b trial

## Summary
- Cash, equivalents, restricted cash only $0.35M as of Sept 30, 2024; net loss $2.7M ($0.51/shr) vs $1.2M ($0.45) YoY.
- R&D expenses fell to $1M from $3.3M; G&A to $2M from $2.7M.
- Signed MOU with Pluri Inc. to manufacture NurOwn for planned Phase 3b ALS trial enrolling ~200 participants.
- Phase 3b: 24-week placebo-controlled part (Part A) then 24-week open-label (Part B); primary endpoint: ALSFRS-R change at week 24.
- Expanded Access data showed median survival 46.6 vs 41.1 months (p=0.0379) and consistent reductions in neurofilament light.

## SEC filing metadata
- accession: 0001104659-24-119041
- form_type: 8-K
- ticker: BCLI
- cik: 0001137883
- company_name: BRAINSTORM CELL THERAPEUTICS INC.
- filed_at: 2024-11-14T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1137883/000110465924119041/0001104659-24-119041-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1137883/000110465924119041/tm2428354d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-24-119041
- JSON: https://secwatch.observer/filing/0001104659-24-119041.json
- Plain text: https://secwatch.observer/filing/0001104659-24-119041.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.